Skip to main content

Table 4 Proportion of variance explained in the QoL parameters by each of the demographic and clinical variables for the boost groups (IORT-EBRT, IORTboost, and EBRTboost; results from univariate linear regression analyses)

From: Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A

  Global health status Restrictions in daily activities General pain Breast symptoms Arm symptoms
Age 3,1%* 2,1% 4,5%* 1% 0,0%
Married/partnered 0,9% 1,6% 1,1% 0,6% 0,3%
Employed 2,4% 3,7%* 4,8%* 0,0% 0,7%
Months since BCS 2,6%* 1,2% 0,3% 1,4% 0,8%
Tumor size 1,3% 0,5% 0,8% 0,2% 0,2%
Nodal involvement 0,6% 0,3% 1,3% 1,3% 0,3%
ALND 1,0% 0,0% 0,0% 0,8% 0,0%
Chemotherapy 3,4%* 3,3%* 4,5%* 0,3% 0,2%
Endocrine therapy 0,0% 0,2% 0,0% 0,7% 0,1%
Radiotherapy of supra- and infraclavicular nodes 1,0% 0,0% 0,2% 0,6% 0,1%
Medical comorbidities ≥2 15,0%** 11,0%** 17,7%** 0,0% 4,9%*
  1. * p < 0,05 in the univariate analysis.
  2. ** p < 0,05 in the univariate and multivariate analyses.